A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== Algorithms and software == Manual de novo sequencing is labor-intensive and time-consuming. Usually algorithms or programs come with the mass spectrometer instrument are applied for the interpretation of spectra.
Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally (by mouth), by intramuscular injection (injection into a muscle), or intravenously (injection into a vein). Chlorpromazine is in the typical antipsychotic class, and, chemically, is one of the phenothiazines. Its mechanism of action is not entirely clear but is believed to be related to its ability as a dopamine antagonist. It has antiserotonergic and antihistaminergic properties. Common side effects include movement problems, sleepiness, dry mouth, low blood pressure upon standing, and increased weight. Serious side effects may include the potentially permanent movement disorder tardive dyskinesia, neuroleptic malignant syndrome, severe lowering of the seizure threshold, and low white blood cell levels. In older people with psychosis as a result of dementia, it may increase the risk of death. It is unclear if it is safe for use in pregnancy. Chlorpromazine was developed in 1950 and was the first antipsychotic on the market. It is on the World Health Organization's List of Essential Medicines. Its introduction has been labeled as one of the great advances in the history of psychiatry.
==== Elimination ==== Suvorexant is eliminated mainly via metabolism. It is excreted primarily in feces (66%) predominantly as metabolites and to a lesser extent in urine (23%). The elimination half-life of suvorexant at a dose of 40 mg is 12.2 hours, with a range of 8 to 19 hours. In another study, the half-life of suvorexant was 15 hours with a range of 10 to 22 hours. In one study, the half-lives of suvorexant (mean ± SD) were 9.0 ± 7.2 hours at 10 mg, 10.8 ± 3.6 hours at 50 mg, and 13.1 ± 5.8 hours at 100 mg. With doses of 120 to 240 mg, the half-lives of suvorexant were 12.1 to 14.5 hours in healthy young males and 14.4 to 15.8 hours in healthy young females. The half-life of suvorexant's inactive metabolite hydroxysuvorexant is similar to that of suvorexant.
== History == Ivar Bang first described the DBS as an unusual sampling method in 1913. The concept that capillary blood, obtained from pricking the heel or finger and blotted onto filter paper, could be used to screen for metabolic diseases in large populations of neonates was introduced in Scotland by Robert Guthrie in 1963. Neonatal screening for phenylketonuria became nationwide in 1969–70. Since then, Guthrie card samples have been collected routinely from infants in over 20 countries to screen for phenylketonuria and more recently for congenital hypothyroidism, sickle cell disorders and HIV infection. The limitations of sensitivity and specificity when screening such small volumes of blood restricted the use of dried blood spots for many years. However, recent advances such as the production of monoclonal antibodies, expression of synthetic proteins, and the introduction of the polymerase chain reaction have overcome many of these problems. This type of blood testing is now available for use at home by consumers in the U.S. Available blood tests include vitamin D, estrogen, testosterone, cortisol, TSH and lipids. New York is the only state that prohibits home blood spot testing.
Sources: en.wikipedia.org
The 1974 Carnation Revolution in Portugal, which over the next year replaced Portuguese support for Smith with an independent, Marxist–Leninist Mozambique on Rhodesia's eastern frontier, greatly swung the war's momentum in favour of the nationalists (particularly ZANU, which was allied with Mozambique's governing FRELIMO party), and caused the sanctions on Rhodesia to finally begin having a noticeable effect. Diplomatic isolation, the sanctions, guerrilla activities and pressure from South Africa to find a settlement led the Rhodesian government to hold talks with the various black Rhodesian factions. Abortive conferences were held at Victoria Falls (in 1975) and Geneva (1976). Despite ideological and tribal rifts, ZANU and ZAPU nominally united as the "Patriotic Front" (PF) in late 1976 in a successful attempt to augment overseas support for the black Rhodesian cause. By the mid-1970s, it was apparent that white minority rule could not continue forever. Even South Africa's prime minister John Vorster realized that white rule in a country where blacks outnumbered whites 22:1 was not a realistic option. Smith, who was decisively re-elected three times during the 1970s, eventually came to this conclusion as well. He announced his acceptance in principle of one man, one vote during Henry Kissinger's Anglo-American initiative in September 1976, and in March 1978 concluded the Internal Settlement with non-militant nationalist groups headed by Bishop Abel Muzorewa, the Reverend Ndabaningi Sithole and Chief Jeremiah Chirau.
== Classification == Structural signs that indicate irreversible cell injury and the progression of necrosis include dense clumping and progressive disruption of genetic material, and disruption to membranes of cells and organelles.
It is most likely that the new allele will be non-functional—in which case it will probably result in low fitness and be removed from the population by natural selection. Alternatively, if the amino acid residue that is changed is in a relatively unimportant part of the enzyme (e.g., a long way from the active site), then the mutation may be selectively neutral and subject to genetic drift. In rare cases, the mutation may result in an enzyme that is more efficient, or one that can catalyse a slightly different chemical reaction, in which case the mutation may cause an increase in fitness, and be favoured by natural selection.
In the Catholic Church, the Dicastery for the Causes of Saints, previously named the Congregation for the Causes of Saints (Latin: Congregatio de Causis Sanctorum), is the dicastery of the Roman Curia that oversees the complex process that leads to the canonization of saints, passing through the steps of a declaration of "heroic virtues" and beatification. After preparing a case, including the approval of miracles, the case is presented to the pope, who decides whether or not to proceed with beatification or canonization.
Rinck PA (ed.). "MRI: A Peer-Reviewed, Critical Introduction". European Magnetic Resonance Forum (EMRF)/The Round Table Foundation (TRTF). A Guided Tour of MRI: An introduction for laypeople National High Magnetic Field Laboratory The Basics of MRI. Underlying physics and technical aspects. Video: What to Expect During Your MRI Exam from the Institute for Magnetic Resonance Safety, Education, and Research (IMRSER) Royal Institution Lecture – MRI: A Window on the Human Body A Short History of Magnetic Resonance Imaging from a European Point of View How MRI works explained simply using diagrams Real-time MRI videos: Biomedizinische NMR Forschungs GmbH. Paul C. Lauterbur, Genesis of the MRI (Magnetic Resonance Imaging) notebook, September 1971 (all pages freely available for download in variety of formats from Science History Institute Digital Collections at digital.sciencehistory.org) Images showing early MRI scans and the development of the MRI scanner from the archives of University of Nottingham Manuscripts and Spcial Collections Archive collections relating to the development of MRI at the University of Nottingham, including the papers of Nobel Prize winner Sir Peter Mansfield
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.